雌激素硫酸基转移酶及孕激素受体蛋白表达与子宫肉瘤发病关系研究  

Correlation between expression of SULT1E1 and progesterone receptor protein and the incidence of uterine sarcoma

作　　者：闫大晶[1,2] 宋燕[1] 王敏[1] 周莹莹[1] 冷旭[1] 

机构地区：[1]中国医科大学附属盛京医院妇产科,辽宁沈阳110004 [2]武警辽宁总队医院妇产科,辽宁沈阳110034

出　　处：《中国实用妇科与产科杂志》2015年第7期657-659,共3页Chinese Journal of Practical Gynecology and Obstetrics

摘　　要：目的探讨雌激素硫酸基转移酶(SULT1E1)和孕激素受体蛋白(PR)在子宫肉瘤组织中的表达并分析其与子宫肉瘤发病的相关性。方法选取2001—2010年中国医科大学附属盛京医院妇产科收治的子宫肉瘤病人石蜡病理切片46例(子宫内膜间质肉瘤31例,子宫平滑肌肉瘤15例),取宫颈上皮内瘤变(CIN)Ⅲ级或子宫脱垂病人的正常子宫肌层组织石蜡病理切片20例作为对照。用免疫组化法对子宫肉瘤组织的SULT1E1、PR蛋白进行检测。结果子宫内膜间质肉瘤组及子宫平滑肌肉瘤组分别与正常子宫肌层组SULT1E1蛋白阳性率比较,差异均有统计学意义(均P<0.05);子宫内膜间质肉瘤组与子宫平滑肌肉瘤组PRA蛋白、PRB蛋白阳性率比较差异均有统计学意义(均P<0.05)。子宫内膜间质肉瘤组织中SULT1E1与PRA、PRB蛋白之间均呈负相关关系(分别r=-0.389,P=0.031;r=-0.421,P=0.018)。结论子宫肉瘤的发生、发展与子宫肉瘤组织SULT1E1蛋白表达降低或缺失有关;在子宫内膜间质肉瘤组织中SULT1E1的表达与孕激素受体A、B表达均呈负相关。Objective To analyze the expression of SULT1E1 and PRA,PRB receptor protein in uterine sarcoma in order to find their clinical significance.Methods Select paraffin biopsy in 46 cases of uterine sarcoma from 2001 to 2010 in Shengjing Hospital of China Medical University.The immunohistochemical methods was used to detect the expressions of sulfotransferaseslE1 and PRA and PRB. Results There was a significant difference in SULT1E1 receptor protein expression between the endometrial stromal sarcoma groups, leiomyosarcoma groups, uterine carcinosarcoma groups and normal groups （P〈0.05）.There was a significant difference of PRA and PRB receptor protein expression between the endometrial stromal sarcoma groups, leiomyosarcoma groups and uterine carcinosarcoma groups （P〈0.05）.In endometrial stromal sarcoma, there was a negative correlation between SULT1E1 and PRA and PRB （r=-0.389, P=0.031 ; r=-0.421, P=0.018, respectively）.Conclusion The decrease or deletion of SULT1E1 receptor protein expression is related to the development of uterine sarcoma.The expression SULTIE1 and that of PRA and PRB have significantly negative correlation in endometrial stromal sarcoma.

关 键 词：子宫肉瘤 孕激素受体A 孕激素受体B 人雌激素硫酸基转移酶 免疫组化 

分 类 号：R737.3[医药卫生—肿瘤]